Seeking Alpha

Premarket weakness in Celsion (CLSN) is attributed to a article suggesting taking...

Premarket weakness in Celsion (CLSN) is attributed to a article suggesting taking profits ahead of Jan. trial results for its ThermoDox drug candidate for treatment of primary liver cancer. Also, CLSN shares have more than doubled since mid-November. CLSN -6.9% premarket.
Comments (3)
  • TonyGail
    , contributor
    Comment (1) | Send Message
    We all know the inherent risk. Sounds like the shorts are panicking a bit and need to drive the price down. Bet they never thought it would get this high.
    Strong Hold
    14 Dec 2012, 09:36 AM Reply Like
  • mjolnir5
    , contributor
    Comments (2) | Send Message
    I agree. I don't think there is anything wrong with taking one's cost basis (and maybe a bit of profit) off the table with such a nice run up. I'll be leaving the bulk of my shares (free shares) in play waiting for results. If I was going to take my profits early and run prior to results I don't think it would do so this early. There are, at minimum, two weeks left prior to the results of Heat released, more than likely a couple more weeks than that. With CLSN who knows how much more it could climb in that time. I'd at least wait out the rest of the month and see if this run up continues. Who knows if another insider buy, or notable press coverage could vault this another dollar by then.
    14 Dec 2012, 12:28 PM Reply Like
  • bbarsher
    , contributor
    Comments (2) | Send Message
    passionately interested in life-sciences
    as a celebrant of Life
    14 Dec 2012, 12:20 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs